Mesalazine plus Lactobacillus casei

ApprovedSmall molecule

Mesalazine plus Lactobacillus casei is one of 5 small molecule programs targeting Diverticular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diverticular DiseaseActive, not recruiting

Diverticular DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Diverticular Disease

#DrugCompanyPhaseTrials

Lialda

Takeda

Phase 2

1 2

Lactobacillus Casei

GGeorgetown University

Approved

1 3

Mesalazine plus Lactobacillus casei

HHospital Cristo Re

Approved

1 4

Xifaxan

SSalix

Preclinical

2 5

Mesalazine

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diverticular Disease1 trial

Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon

Completed·HHospital Cristo Re·Phase 4·NCT01534754·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mesalazine plus Lactobacillus casei. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mesalazine plus Lactobacillus casei compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mesalazine plus Lactobacillus casei. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Cristo Re company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHospital Cristo Re

Mesalazine plus Lactobacillus casei

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Diverticular Disease1 trial

References

Drug Info

Quick Facts

Related News